| Full text | |
| Author(s): |
Correa, Mab P.
[1]
;
Areias, Libnah L.
[2]
;
Correia-Silva, Rebeca D.
[2]
;
D'Avila, Solange C. G. P.
[3]
;
Leopoldino, Andreia M.
[4]
;
Greco, Karin V.
[5]
;
Gil, Cristiane D.
[1, 2]
Total Authors: 7
|
| Affiliation: | [1] Univ Estadual Paulista UNESP, Inst Biociencias Letras & Ciencias Exatas, Programa Posgrad Biociencias, BR-15054000 Sao Jose Do Rio Preto, SP - Brazil
[2] Univ Fed Sao Paulo UNIFESP, Escola Paulista Med, Dept Morfol & Genet, BR-04023900 Sao Paulo, SP - Brazil
[3] Fac Med Sao Jose do Rio Preto FAMERP, Dept Patol & Med Forense, BR-15090000 Sao Jose Do Rio Preto, SP - Brazil
[4] Univ Sao Paulo, Dept Anal Clin Toxicol & Bromatol, Fac Ciencias Farmaceut Ribeirao Preto, BR-14040903 Ribeirao Preto, SP - Brazil
[5] Univ Coll London UCL, Griffin Inst, Div Surg & Intervent Sci, London HA13UJ - England
Total Affiliations: 5
|
| Document type: | Journal article |
| Source: | CELLS; v. 10, n. 4 APR 2021. |
| Web of Science Citations: | 0 |
| Abstract | |
Galectin-9 (Gal-9) is a beta-galactoside-binding protein with a variety of biological functions related to immune response. However, in allergic diseases, its mechanism of action is not fully understood. This study evaluates the expression pattern of Gal-9 in patients with atopic dermatitis (AD), in ovalbumin (OVA)-induced experimental atopic dermatitis (AD) in mice, as well as its effect on human keratinocytes. The skin of OVA-immunized BALB/c mice was challenged with drops containing OVA on days 11, 14-18, and 21-24. HaCaT cells were cultured in the following experimental conditions: control (growth medium only) or stimulated with TNF-alpha/IFN-gamma, or IL-4, or IL-17 with or without Gal-9 treatment. AD was characterized by increased levels of Gal-9 in mouse and human skin, especially in the epidermis, and with a marked influx of Gal-9 positive eosinophils and mast cells compared to the control group. Gal-9 showed an immunomodulatory effect on keratinocytes by decreasing the release of IL-6 by IL-4-stimulated keratinocytes or increasing the IL-6 and RANTES levels by IL-17- or TNF-alpha/IFN-gamma-stimulated cells, respectively. Under IL-17, Gal-9 treatment also altered the proliferation rate of cells. Overall, increased levels of Gal-9 in AD skin contribute to the control of inflammatory response and the proliferative process of keratinocytes, suggesting this lectin as a relevant therapeutic target. (AU) | |
| FAPESP's process: | 17/26872-5 - Study of anti-inflammatory and proinflammatory proteins as possible therapeutic targets in experimental models of neuroinflammation and cutaneous inflammation |
| Grantee: | Cristiane Damas Gil |
| Support Opportunities: | Regular Research Grants |
| FAPESP's process: | 17/10610-1 - Study of galectin-9 in experimental atopical dermatitis treated or not with dexamethasone |
| Grantee: | Libnah Leal Areias |
| Support Opportunities: | Scholarships in Brazil - Scientific Initiation |